The alpha-blocker, known as silodosin, works by selectively relaxing the muscles in the bladder neck and prostate. The treatment is already approved in Canada, the United States, the EU and Japan to treat painful symptoms of another prostate gland condition, benign prostatic hyperplasia, commonly referred to as an enlarged prostate.
Despite being the most common form of prostatitis, CP/CPPS is the most misunderstood and difficult to treat because the symptoms are very similar to other conditions and requires a significant degree of testing and screening to identify.
"Antibiotics are commonly used as a treatment, but are not typically effective, probably because CP/CPPS does not seem to be caused by a bacterial infection," explains lead researcher Curtis Nickel, a professor in the Department of Urology, practicing urologist at Kingston General Hospital, and Canada Research Chair in Urologic Pain and Inflammation.
CP/CPPS is a debilitating condition characterized by persistent discomfort in the lower pelvic area including the bladder area, testicles, and penis. Symptoms can be severe and include painful and frequent urination and difficult or painful ejaculation. The cause of the condition is unknown.
In Dr. Nickel's study, approximately 60 per cent of men reported feeling better after treatment with silodosin versus 30 per cent of participants who were given a placebo. The number of patients who reported feeling better is higher than in a similar study he ran several years ago that tested the effects of a different alpha blocker.
Dr. Nickel, along with his Prostatitis Research Group at Kingston General Hospital and Queen's University, has been studying CP/CPPS for the past two decades. He has been the principal investigator of over a dozen international clinical trials evaluating therapies for chronic prostatitis. His research studies are supported by the Canadian Institute of Health Research, US National Institutes of Health and industry, including Watson Pharmaceuticals who provided the support for this particular clinical trial.
Dr. Nickel presented his results at today's American Urological Association annual meeting in Washington DC. The study results will appear in an upcoming issue of the Journal of Urology.
Christina Archibald | EurekAlert!
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences
07.12.2016 | Health and Medicine